STXBP5

Across TCGA pan-cancer cohorts, STXBP5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STXBP5 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STXBP5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STXBP5 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where STXBP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.548	0.777	.028	15	view →
PDAC	OS	Tertile	IV	0.973	0.395	.024	6	view →
LUAD	OS	Median	All	0.889	0.995	.025	5	view →
LSCC	DFS	Tertile	II,III,IV	0.528	0.846	.040	4	view →
CCRCC	OS	Quartile	III,IV	0.273	0.720	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STXBP5–HNSC (DFS)

Open the HNSC breakdown →